MEI Pharma, Inc. (0JW9.L)

3.2328 -0.5387 (-14.28%) As of 06:27PM BST. Market open.

MEI Pharma, Inc.

11455 El Camino Real
Suite 250
San Diego, CA 92130
United States
858 369 7100
https://www.meipharma.com

Sector(s): 
Industry: 
Full-time employees: 46

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David M. Urso B.A., Esq., J.D.	CEO, President & Director	748.46k	N/A	1964
Dr. Richard G. Ghalie M.D., MBA	Chief Medical Officer	627.76k	N/A	1958
Mr. Justin J. File	CFO & Corporate Secretary	N/A	N/A	1970
Ms. Yomara Gomez-Naiden	Senior Vice President of Operations & Quality	N/A	N/A	N/A
Ms. Nicole Chyoko Iida	Vice President of Legal Affairs	N/A	N/A	N/A
Ms. Anne Frese	Chief People Officer	N/A	N/A	N/A
Dr. Robert D. Mass	Strategic Advisor	201.68k	N/A	1954
Mr. David A. Walsey J.D., L.L.M.	Senior Vice President of Corporate Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Corporate governance

MEI Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.